marimastat has been researched along with rs-130830 in 3 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (rs-130830) | Trials (rs-130830) | Recent Studies (post-2010) (rs-130830) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 19 | 0 | 8 |
| Protein | Taxonomy | marimastat (IC50) | rs-130830 (IC50) |
|---|---|---|---|
| Collagenase 3 | Bos taurus (cattle) | 0.004 | |
| Interstitial collagenase | Homo sapiens (human) | 0.2062 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.0001 | |
| Stromelysin-1 | Homo sapiens (human) | 0.0533 | |
| Matrilysin | Homo sapiens (human) | 0.9325 | |
| Stromelysin-2 | Homo sapiens (human) | 0.0005 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.0463 | |
| Neutrophil collagenase | Homo sapiens (human) | 0.0001 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.014 | |
| Collagenase 3 | Homo sapiens (human) | 0.0367 | |
| Matrix metalloproteinase-14 | Homo sapiens (human) | 0.0043 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.1316 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barta, TE; Becker, DP; Bedell, LJ; De Crescenzo, GA; McDonald, JJ; Munie, GE; Rao, S; Shieh, HS; Stegeman, R; Stevens, AM; Villamil, CI | 1 |
| Barta, TE; Becker, DP; Bedell, LJ; De Crescenzo, GA; McDonald, JJ; Mehta, P; Munie, GE; Villamil, CI | 1 |
| Charton, J; Dassonneville, S; Deprez, B; Deprez-Poulain, R; Flipo, M; Hocine, A | 1 |
3 other study(ies) available for marimastat and rs-130830
| Article | Year |
|---|---|
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
Topics: Antineoplastic Agents; Collagenases; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Matrix Metalloproteinase 1; Matrix Metalloproteinase 13; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Models, Molecular; Structure-Activity Relationship | 2000 |
Selective, orally active MMP inhibitors with an aryl backbone.
Topics: Administration, Oral; Animals; Biological Availability; Drug Design; Matrix Metalloproteinase 13; Matrix Metalloproteinase Inhibitors; Piperidines; Protease Inhibitors; Rats; Structure-Activity Relationship; Sulfhydryl Compounds | 2001 |
Hydroxamates: relationships between structure and plasma stability.
Topics: Animals; Drug Evaluation, Preclinical; Drug Stability; Esterases; Half-Life; Humans; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Hydroxamic Acids; Plasma; Prodrugs; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2009 |